Abstract: In this article, the recursive problems of both orthogonal linear discriminant analysis (OLDA) and orthogonal least squares regression (OLSR) are investigated. Different from other works, ...

British mathematician Jack Good coined the term “intelligence explosion” 61 years ago to describe what would happen when an intelligent machine entered a runaway cycle of fully automated ...

Recursion Pharmaceuticals is trying to solve a serious problem. Even with technological improvements, the time and costs required to develop brand-new drugs have increased in recent decades. It can ...

One of the key challenges of current multi-agent AI systems is that they communicate by generating and sharing text sequences, which introduces latency, drives up token costs, and makes it difficult ...

Recursive Superintelligence Inc., a startup that hopes to develop self-improving artificial intelligence models, launched today with $650 million in funding. Alphabet Inc.’s GV fund and Greycroft led ...

Penn researchers have developed a smarter AI method for solving notoriously difficult inverse equations, which help scientists uncover hidden causes behind observable effects. By introducing ...

Great. Thanks, everyone, for joining. My name is Scott Schoenhaus. I am the health care tech equity analyst here at KeyBanc. We're a pleasure to have Ben Taylor, CFO of Recursion for a fireside chat.

A decision tree regression system incorporates a set of if-then rules to predict a single numeric value. Decision tree regression is rarely used by itself because it overfits the training data, and so ...

We support Finterion as our go-to marketplace for quantitative trading and trading bots. Works with the Investing Algorithm Framework PyIndicators works natively with the Investing Algorithm Framework ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...

Recursion Pharmaceuticals has significantly lagged the market since its 2021 IPO. The company's potentially revolutionary approach has yet to produce results. The stock's upside is enormous if ...